Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men

Aiman El-Saed, Akira Sekikawa, Riad Wahid Zaky, Takashi Kadowaki, Tomoko Takamiya, Tomonori Okamura, Daniel Edmundowicz, Yoshikuni Kita, Lewis H Kuller, Hirotsugu Ueshima, Aiman El-Saed, Akira Sekikawa, Riad Wahid Zaky, Takashi Kadowaki, Tomoko Takamiya, Tomonori Okamura, Daniel Edmundowicz, Yoshikuni Kita, Lewis H Kuller, Hirotsugu Ueshima

Abstract

Background: We have previously reported that the prevalence of coronary artery calcification (CAC) was substantially lower among Japanese than American men despite a less favorable profile of many traditional risk factors in Japanese men. To determine whether lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are related to the difference in the prevalence of CAC between the two populations.

Methods: A total of 200 men aged 40-49 years were examined: 100 residents in Allegheny County, Pennsylvania, United States, and 100 residents in Kusatsu City, Shiga, Japan. Coronary calcium score (CCS) was evaluated by electron-beam tomography, Lp-PLA2 levels, nuclear magnetic resonance (NMR) lipoprotein subclasses, and other factors were assessed in 2001-2002.

Results: Lp-PLA2 levels were higher among American than Japanese men (Mean +/- standard deviation 301.7 +/- 82.6 versus 275.9 +/- 104.7 ng/mL, respectively, p=0.06). Among all Japanese men and those with low density lipoprotein (LDL) cholesterol > or =130 mg/dL, there was an inverse association of the prevalence of CCS>0 with the tertile groups of Lp-PLA2 levels (p=0.08 and p=0.03, respectively). American men did not have any association between CCS>0 with the tertile groups of Lp-PLA2 (p=0.62). Although Lp-PLA2 among both populations correlated positively with LDL and total cholesterol, American and Japanese men had different correlations with NMR lipoprotein subclasses. Reported high odds ratio for CCS>0 among American compared to Japanese men was not reduced after adjusting for Lp-PLA2 levels.

Conclusion: Lp-PLA2 may have different mechanisms of action among American and Japanese men. Lp-PLA2 levels can not explain the observed CAC differences between the two populations.

Figures

Figure 1.. Prevalence of those with coronary…
Figure 1.. Prevalence of those with coronary calcium score (CCS) > 0 among the 2 populations by tertile group of lipoprotein-associated phspholipase A2 (Lp-PLA2): all participants.
Figure 2.. Prevalence of those with coronary…
Figure 2.. Prevalence of those with coronary calcium score (CCS) > 0 among the 2 populations by tertile group of lipoprotein-associated phspholipase A2 (Lp-PLA2): those with low density lipoprotein cholesterol ≥ 130 mg/dL.

References

    1. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. . Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774-82. 10.1172/JCI117726
    1. Zalewski A, Macphee C.. Role of lipoprotein-associated phospholipase A(2) in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-31. 10.1161/01.ATV.0000160551.21962.a7
    1. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, et al. . Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374: 549-53. 10.1038/374549a0
    1. Yamada Y, Ichihara S, Fujimura T, Yokota M.. Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998; 47: 177-81. 10.1016/S0026-0495(98)90216-5
    1. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M.. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000; 150: 209-16. 10.1016/S0021-9150(99)00385-8
    1. Unno N, Nakamura T, Kaneko H, Uchiyama T, Yamamoto N, Sugatani J, et al. . Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. J Vasc Surg 2000; 32: 263-7. 10.1067/mva.2000.105670
    1. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K.. A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke. Stroke 1997; 28: 2417-20. 10.1161/01.STR.28.12.2417
    1. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, et al. . The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 2000; 66: 1522-30. 10.1086/302901
    1. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C.. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110: 1903-8. 10.1161/01.CIR.0000143377.53389.C8
    1. Oei HHS, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. . Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke - The Rotterdam Study. Circulation 2005; 111: 570-5. 10.1161/
    1. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000; 150: 413-9. 10.1016/S0021-9150(99)00406-2
    1. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005; 26: 137-44. 10.1093/eurheartj/ehi010
    1. Khuseyenova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, et al. . Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005; 182: 181-8. 10.1016/j.atherosclerosis.2004.10.046
    1. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, et al. . Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors - The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005; 111: 980-7. 10.1161/01.CIR.0000156457.35971.C8
    1. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001; 38: 1302-6. 10.1016/S0735-1097(01)01554-6
    1. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. . Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42. 10.1161/01.CIR.0000116763.91992.F1
    1. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. . Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006; 113: 1745-52. 10.1161/CIRCULATIONAHA.105.612630
    1. Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: The CARDIA study. Arteriosclerosis Thrombosis and Vascular Biology 2005; 25: 216-21.
    1. Kardys I, Oei HH, Hofman A, Oudkerk M, Witteman JC. Lipoprotein-associated phospholipase A2 and coronary calcification The Rotterdam Coronary Calcification Study. Atherosclerosis 2006;May 3.
    1. Sekikawa A, Ueshima H, Zaky WR, Kadowaki T, Edmundowicz D, Okamura T, et al. . Much lower prevalence of coronary calcium detected by electron-beam computed tomography among men aged 40-49 in Japan than in the US, despite a less favorable profile of major risk factors. Int J Epidemiol 2005;34:173-9. 10.1093/ije/dyh285
    1. Worth RM, Kato H, Rhoads GG, Kagan K, Syme SL. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: mortality. Am J Epidemiol 1975;102:481-90.
    1. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32. 10.1016/0735-1097(90)90282-T
    1. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M.. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42: 93-114. 10.1016/S0163-7827(02)00049-8

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever